G. Simonneau

Pulmonary and Respiratory Medicine · 2001–2022

A researcher in the Science corpus: 32 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Pulmonary and Respiratory Medicine — 270 citations into it; #739 of 770 by trust here, #17 by citations

Whom G. Simonneau trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. N. Galiè

Who trusts G. Simonneau overall

1. N. Galiè

Papers from G. Simonneau's perspective

Ordered by how strongly the researchers G. Simonneau trusts endorse each paper. Same corpus, a different order for every researcher.

1. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. (Journal of the American College of Cardiology)
2. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (European Respiratory Journal)
3. SF-36 health survey: Manual and interpretation guide
4. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. (Annals of Thoracic Surgery)
5. Linear Mixed Models for Longitudinal Data (Technometrics)
6. Reference equations for the six-minute walk in healthy adults.
7. Updated clinical classification of pulmonary hypertension. (Journal of the American College of Cardiology)
8. Chronic thromboembolic pulmonary hypertension. (Seminars in Respiratory and Critical Care Medicine)
9. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (New England Journal of Medicine)
10. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. (The Lancet)

Their papers

• Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. (2001) — 703 citations
• 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. (2022) — 3,323 citations
• 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022) — 1,388 citations
• Haemodynamic definitions and updated clinical classification of pulmonary hypertension (2019) — 3,207 citations
• Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension (2017) — 614 citations
• 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2015) — 2,848 citations
• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015) — 1,025 citations
• Selexipag for the Treatment of Pulmonary Arterial Hypertension. (2014) — 881 citations
• Pulmonary hypertension due to left heart diseases. (2013) — 608 citations
• Macitentan and morbidity and mortality in pulmonary arterial hypertension. (2013) — 1,290 citations
• Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. (2013) — 1,261 citations
• Pulmonary arterial hypertension (2013) — 1,592 citations
• Pulmonary Arterial Hypertension in Patients Treated by Dasatinib (2012) — 606 citations
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry (2011) — 966 citations
• Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. (2011) — 700 citations
• Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension (2010) — 666 citations
• Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era (2010) — 1,409 citations
• Tadalafil Therapy for Pulmonary Arterial Hypertension (2009) — 1,037 citations
• Updated clinical classification of pulmonary hypertension. (2009) — 3,966 citations
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008) — 596 citations